MDXG News and Press, MiMedx Group Inc

Issued on behalf of Conexeu Sciences Inc. A sector analysis of regenerative medicine — the science of restoring tissue rather than merely replacing it — and where a new generation of platform companies is trying to fit in. NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Biotech ...

Issued on behalf of Conexeu Sciences Inc. A new generation of tissue companies is betting that the future of wound care and reconstruction isn't a better patch — it's a material that helps the body regrow itself. One newly public name just took a concrete step toward proving it. NEW...

2026-06-09 11:19:59 ET NEW YORK, June 09, 2026 — Equity Insider News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from ...

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc...

The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts PR Newswire Issued on behalf of Conexeu Sciences Inc. A newly listed regenerative-tissue company has put its lead breast-reconstruction matrix on the bench at one of the world ' s...

MARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the  Craig-Hallum 23 rd Annual Institutional Investor Conference on Thursd...

2026-05-09 05:04:28 ET MiMedx Overview When I last wrote about MiMedx Group ( MDXG ), I thought its stock was on the verge of a breakout. The company was growing at a CAGR of 14%, profitable, and revenue growth was outpacing opex growth (signaling operating leverage).... R...

Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company’s Portfolio G4Derm Plus Added to Premier and Vizient GPO Agreements MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”)...

MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company&#x...

2026-04-29 23:43:02 ET More on MiMedx Group MiMedx Group, Inc. (MDXG) Q1 2026 Earnings Call Transcript MiMedx Group, Inc. (MDXG) Q4 2025 Earnings Call Transcript MiMedx Group Non-GAAP EPS of -$0.05 misses by $0.01, revenue of $59M misses by $6.8M MiMedx Group...